Hypoxanthine

68-94-0

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterpri♥se that is market-oriented and realizes industrial development throughΩ R&D innovation and technology transformation.

key word:

Pharmaceutical technology

Category:

Product Description

Integrity, innovation, cooperation, sharing, win-win♠

The company integrates multiple resources and strives to build a large health industry finance p↓latform company integrating pharmaceutical, intelligent medical, bio pharmaceutical R&D, in±dustrial production and sales.

The chemical reactions involved in the existing products include Foucault reacti♦on, nitration reaction, sulfonation reaction, hydrogenatio±n reaction, fluorination reaction, chlorination reaction, bromination reaction, diazotizatio₽n reaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck. In Octobe‌r 2006, Sitagliptin phosphate Januvia was approved by FDA as the first DPP4 ≤inhibitor for the treatment of type ⅱ diabetes mellitus. The character"istics of this drug are that it can stimulate insulin secre÷tion while reducing hunger without causing weight gain. Hypoglycem"ia and edema will not occur, and it is suitable for diabetic< patients with poor blood glucose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that' is market-oriented and realizes industrial development through ♦R&D innovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most important ¥products for the treatment of arthritis. It is well tolerated and has a loπw incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor antagonists. In clini♦cal application, it has good therapeutic effect on atopic asthma and other types of bronchial a"sthma, and the market prospect is huge. In the major category o f asthma drugs, leukotriene receptor antagonists ha™ve the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceuti♦cal enterprise that is market-oriented and realizes industrial development through R&D÷ innovation and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the& second drug approved by FDA for Alzheimer's disease in the United States. Its treatment reachπes the target dose and has low toxic and side effects. It has' been widely recognized by our medical community, and good t¥olerance is its biggest advantage. In October 1999, Donepezil  was launched in China under the trade name "Aricept", which is the main cheλmical drug against Alzheimer's disease. At present, CFDA has approved a number of d¶omestic enterprises to produce donepezil preparati←ons, the main dosage forms are tablets, capsules, dispersive tablets, oral di₩sintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squi≈bb/Pfizer), a direct oral factor Xa inhibitor, was approvπed for use in the 27 EU member states. The world's first drug approved to prevent venou♣s thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement. Fro‌m June 2019 to June 2020, the annual sales of apixaban product♥s overseas reached about $15.4 billion, with a year-on-year growth of nearly 32%, and the λAPI consumption reached about 23,960 kg, with a year-on-≠year growth of about 28%. Compared with its main competitor, Rivaroxaban, the drug's annual oveβrseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is ma∑rket-oriented and realizes industrial development through R&D innovation and technology tra<nsformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by ×Genzyme. On December 29, 2004, it was approved by FDA for the treatment of refracto↔ry or relapsed acute lymphoblastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-orien♦ted and realizes industrial development through R&D innovation and technology transf"ormation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need other servi₽ces, E-mail: 2880705932@qq.com
Submit

Copyright © 2022 Anhui Union Pharmaceuticals Technology Co., Ltd.